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The effect of chemotherapy on numerical aberrations 
of spermatozoal chromosomes in testicular cancer patients
Tomasz Demkow1, Maria Constantinou2, Bogdan Ka∏u˝ewski2
I n t r o d u c t i o n.  The incidence of germinal cell tumours of the testes reaches its peak in men between 20 and 40 years of age,
constituting some 95% of all testicular malignancies. During the last 20 years the results of treatment of testicular malignancies
have improved dramatically, the cure rate reaching 95% in patients staged as grades I and II and approximately 80% in
patients staged as grade III.
The aim of the study was to evaluate the frequency of aneuploidy of chromosomes 13, 18, 21, X and Y in the seminal
smears of patients with testicular cancer and in healthy controls, and then to analyze chromosomal numerical aberrations of
chromosomes 13, 18, 21, X and Y after chemotherapy.
M a t e r i a l .   The material constituted of 20 men with testicular cancer, who underwent evaluation of seminal smears for the
frequency of chromosomal aberrations (13, 18, 21, X and Y) prior to and 30 months after the completion of chemotherapy
(chth). During chemotherapy the patients received two courses of carboplatin or two to six courses of BEP (cis-platin,
etoposide and bleomycin).
Re s u l t s.  We found no differences in the frequency of chromosomal numerical aberrations among the healthy men and the
testicular cancer patients both prior to, and after the completion of chemotherapy; the cells with chromosomal numerical
aberrations accounting for 1.76%, 2% and 2.09%, respectively.
Among the aneuploid spermatozoa we found hypohaploid, hyperhaploid and diploid cells. The ratio of each of the cell
types was, respectively, 0.40%; 0.40% and 0.45% in the control group; 0.73%, 0.91% and 0.97% in the “prior to chth” group
and 0.63%; 0.69% and 0.67% in the “post chth” group.
Autosomal (13, 18 and 21) disomy was observed in a total of 0.64% of spermatozoa of the control group subjects and in
0.74% and 0.83% of the study group prior to and after chth, respectively.
The frequency of nullsomy of chromosomes 13, 18 and 21 was 0.29% in the control group, 0.24% in the “prior to chth” group
and 0.17% in the “post chth” group.
The X/Y ratio was found to be 50%/50% in all the three groups. The frequency of X and Y nullsomy was 0.14% in the control
group, 0.19% in the “prior to chth” group and 0.13% in the “post chth” group. In the control group the diploid spermatozoa
were discerned as XX in 0.05%; as XY in 0.49% and as YY in 0.09%. In the studied group “prior to chth” the same values
reached 0.09%; 0.5% and 0.07% respectively, while in the “post chth” group they reached 0.09%; 0.49% and 0.07%,
respectively.
In germinal cell tumour patients 30 months after platinum-based chemotherapy the risk of producing a child with 13, 18, 21,
X or Y chromosome aneuploidy of the father’s origin is low.
C o n c l u s i o n s.  1. Aneuploidy of chromosomes 13, 18, 21, X and Y is equally frequent in healthy males and in germinal cell
tumour patients. 2. Platinum-based chemotherapy does not influence the frequency of aneuploidy of chromosomes 13, 18, 21,
X and Y in the spermatozoa of germ cell tumour patients 30 months after treatment completion.
Wp∏yw chemioterapii na aberracje liczbowe chromosomów plemnikowych
u chorych na nowotwory jàdra
Najwi´kszy odsetek zachorowaƒ na nowotwory zarodkowe jàdra wyst´puje u m´˝czyzn w wieku 20-40 lat. Nowotwory te
stanowià 95% wszystkich nowotworów jàdra.
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Introduction
In 1996 564 new cases of germinal cell tumours were
diagnosed in Poland [1], their incidence listing them as the
eighteenth most common malignancy and recognized as
the 29th most common cause of death [1]. The peak of
incidence is noted in subjects between 20 and 40 years
of age and in those over the age of 60 [2]. Germinal cell
tumours account for 95% of all testicular malignancies [2].
During the last 20 years the results of treatment of
testicular malignancies have improved dramatically. In
the beginning of the 1970’s the cure rate hovered around
10%, while at present it reaches 95% in patients in the
first and second stage of the disease and approximately
80% in patients in the third stage [3-5].
Young germinal cell tumour survivors (aged between
18 and 35 years) more and more often state their will to
father children, and therefore both they, and their
partners, seek to know their ability to produce healthy
offsprings. Oncolytic drugs are rightly perceived as serious
mutagens, while cells undergoing rapid division, such as
those of the spermatogenetic epithelium, are at a greater
risk of damage of their genetic apparatus. This is of
extreme importance, because the damaged genetic
material may find its way into reproductive cells, thus
causing reproductive disturbances (embryonic death or
congenital defects in the offspring). Because the sperma-
togenic epithelium originates from stem cell division, any
genetic defect at this latter level may continue to be
reproduced, thus causing repeated reproduction failures
[6-8].
Among all the cells taking part in spermatogenesis
the spermatogoniums and the primary spermatocytes in
the preleptoten period are most likely to be affected by
cytostatic drugs, as they undergo rapid divisions [10-12].
On the other hand, DNA and the chromosomes of
secondary spermatocytes and spermatids are less prone to
damage, as they do not divide so fast.
The DNA of spermatogoniums undergoes damages
throughout the entire period of chemotherapy. This leads
to azoospermia. Once chemotherapy is stopped the entire
population of the reproductive cells should be restored
over a period of 12 weeks. Unfortunately, in those
patients in whom platinum derivatives were applied for
testicular cancer the semen returns to its normal
parameters only after some 2-3 years. We are not yet
aware of the reasons for this delay. It is necessary to stress
that permanent or transient oligo- or azoospermia
depends on the type of drug, its dosage and the duration
of treatment. Abnormalities of the spermatozoal DNA
may affect fertilization and embryonic vitality and
development; they may also influence the probability of
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W ostatnich dwudziestu latach radykalnie poprawi∏y si´ wyniki leczenia chorych na nowotwory z∏oÊliwe jàdra. Obecnie
odsetek wyleczeƒ si´ga 90% w pierwszym i drugim stopniu zaawansowania oraz oko∏o 80% w trzecim stopniu zaawansowania.
C e l.  Celem pracy by∏a ocena cz´stoÊci wyst´powania aneuploidii chromosomów 13, 18, 21, X, Y w rozmazach plemnikowych
grupy kontrolnej i grupy chorych na nowotwór jàdra przed leczeniem. W pracy podano równie˝ analiz´ wp∏ywu chemioterapii
na wyst´powanie aberracji liczbowych chromosomów 13, 18, 21, X, Y.
M a t e r i a ∏.  Materia∏ stanowi∏o 20 m´˝czyzn, którym zbadano cz´stoÊç aberracji chromosomalnych (13, 18, 21, X, Y)
w nasieniu pobranym przed i 30 miesi´cy po zakoƒczeniu chemioterapii. Chorzy leczeni byli dwoma kursami karboplatyny lub
cisplatynà, etopozydem i bleomycynà (BEP) w schemacie dwa, trzy, cztery lub szeÊç kursów BEP.
W y n i k i.  Nie stwierdzono ró˝nic w cz´stoÊci wyst´powania zaburzeƒ liczby chromosomów plemnikowych w grupie zdrowych
m´˝czyzn i w grupie chorych przed i po leczeniu. Komórki wykazujàce zaburzenia liczby chromosomów stanowi∏y 1,76%
w grupie kontrolnej, 2% w grupie przed chemioterapià i 2,09% po chemioterapii.
WÊród plemników aneuploidalnych wyró˝niono komórki hipohaploidalne (k.hipo), hiperhaploidalne (k.hiper), diploidalne
(dip). Odsetek poszczególnych rodzajów komórek w grupie kontrolnej oraz w grupie chorych przed i po chemioterapii
wynosi∏ odpowiednio: k.hipo – 0,40%, k.hiper – 0,40%, dip – 0,45%, k.hipo – 0,73%, k.hiper – 0,91%, dip – 0,97%,
i k.hipo – 0,63%, k.hiper – 0,69%, dip – 0,67%.
Odsetek disomii autosomów (13, 18, 21) obserwowano ogó∏em w 0,64% plemników w grupie kontrolnej, oraz 0,74%
i 0,83% plemników w grupie badanej przed i po chemioterapii.
Odsetek nullosomii chromosomów 13,18,21 w grupie kontrolnej oraz przed i po chemioterapii wynosi∏ 0,29%, 0,24%,
0,17%.
W grupie kontrolnej oraz w grupie chorych przed i po chemioterapii stosunek X/Y wynosi∏ 50% / 50%. Odsetek nullosomii
chromosomów X lub Y wynosi∏ odpowiednio 0,14%, 0,19%, 0,13%. W grupie kontrolnej plemniki z diploidalnym kariotypem,
zawierajàcym chromosomy XX, wyst´powa∏y w 0,05%, chromosomy XY w 0,49% i chromosomy YY w 0,09%. W grupie
chorych przed i po chemioterapii wartoÊci te wynosi∏y odpowiednio 0,09%, 0,5%, 0,07% i 0,09%, 0,49%, 0,07%.
W grupie chorych na nowotwór jàdra po up∏ywie 30 miesi´cy od zastosowanego leczenia preparatami platyny ryzyko urodzenia
dziecka z aneuploidià chromosomów 13, 18, 21, X, Y pochodzenia ojcowskiego jest niskie.
W n i o s k i.  1. Aneuploidia chromosomów 13, 18, 21, X, Y wyst´puje równie cz´sto w grupie zdrowych m´˝czyzn, jak
i chorych na nowotwór jàdra. 2. Chemioterapia preparatami platyny nie wp∏ywa na cz´stoÊç aneuploidii chromosomów 13,
18, 21, X, Y w plemnikach chorych na nowotwór jàdra w 30 miesi´cy po zakoƒczeniu leczenia.
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genetic disorders in the offspring. Spermatozoal DNA
may now be evaluated owing to the development of
cytometric methods (flow cytometry or imaging cyto-
metry). These methods have revealed that abnormal
DNA content may cause disorders in the structure and
mobility of spermatozoa.
Studies aimed at discerning chromosomal
aberrations within the spermatozoa have been conducted
for a number of years. First reports of chromosomal
aneuploidy in human gametes were published in 1980
[13].
Classical cytogenetic studies are conducted on
chromosomes in the metaphase, and their analysis
demands differential staining. At present we use either
striatic analysis or the fluorescent in situ hybrydization
(FISH) techniques, which allow to analyze chromosomal
aberrations in the metaphase and also in interphase
nuclei.
Chromosomal aberrations may be evaluated in
human spermatozoa in the course of analysis of hamster
oocyte penetration (Yanagimachi) or with the use of the
FISH technique. It must be stressed that all these studies
were carried out on very small groups of subjects (4-5
persons) and cannot form the base for definite
conclusions.
Aims of the study
1. To assess the frequency of aneuploidy of chromosomes
in 13, 18, 21, X and Y in seminal smears of testicular
cancer patients as compared to healthy controls.
2. To evaluate the impact of systemic platin-based
chemotherapy on the frequency of numerical aberra-
tions of chromosomes 13, 18, 21, X and Y.
Material
The material included twenty patients with testicular cancer in
whom we analyzed the frequency of chromosome 13, 18, 21, X
and Y aberrations in spermatozoa from seminal samples
obtained before, and 30 months after the completion of
chemotherapy. The results were compared with results observed
in the control group, which consisted of five healthy, fertile men
between the ages of 20 and 30. Table I presents patient data – the
number of spermatozoa present in the samples taken before
and after chemotherapy, the type of applied chemotherapy, the
histopathological types of the tumours and the stage of
advancement of the tumours.
Method
Every patient underwent routine analysis of the ejaculate and
ultrasonographic examination of the healthy testis both before
chemotherapy and 30 months after its completion. After analysis
the seminal sample was preserved in liquid nitrogen until the
time of cytogenetic examination using the FISH technique. The
ejaculates were obtained in the course of masturbation (at least
3 days after previous ejaculation), and routine examination was
performed acc. to WHO standards after complete liquefaction
[14]. Morphology of the spermatozoa was assessed after
Pappenheim staining. The minimal number of examined
spermatozoa per sample was 200. We applied the University of
Minnesota modified system of clinical staging for germinal
tumours of the testes. The results of the general examination of
seminal samples of testicular cancer patients (obtained both
prior to and after orchidectomy) were compared with analogous
results from samples obtained from five healthy individuals.
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Table I. Data of 20 testicular cancer patients in whom the frequency of chromosomal aberrations was analyzed (incl: number of spermatozoa,
tumour pathology, grade of advance, type of chemotherapy)
Pt. number Age (yrs.) A B Pathology Grade Type of chth.
1 31 57 70 Non-S IIC 3xBEP
2 22 56 28 Non-S 1H 2xBEP
3 45 62 140 S 1H 2xkarbo
4 32 87 19 Non-S IIIA 4xBEP
5 20 19.5 4 Non-S IIIB 4xBEP
6 30 84 50 Non-S IIB 3xBEP
7 18 225 85 Non-S 1H 2xBEP
8 22 4.7 15 Non-S IIIA 4xBEP
9 34 37.5 33 Non-S IIIA 4xBEP
10 22 3.7 20 Non-S IIA 3xBEP
11 39 34 10 S IIIA 4xBEP
12 28 12 18 S 1H 2xkarbo
13 22 49 15 S IIB 3xBEP
14 23 7 10 Non-S IIIB 4xBEP
15 26 20 12 Non-S 1H 2xkarbo
16 30 5.6 39 Non-S 1H 2xBEP
17 30 41 18 S 1H 2xkarbo
18 20 30 70 Non-S 1H 2xkarbo
19 28 6.7 14 Non-S 1H 2xkarbo
20 22 21 18 S IIA 3xBEP
A – number of spermatozoa in 1 ml of semen before chemotherapy x 106
B – number of spermatozoa in 1 ml of semen after chemotherapy x 106
Grade – grade of clinical advancement
S – seminoma
Non-S – non-seminoma
BEP – bleomycin, cisplatin, etopozyd
Karbo – carboplatin
The following chemotherapy regimes were applied:
1. Two courses of carboplatin – dose: 400 mg/m2
2. BEP – cis-platin: 100 mg/m2; fractionated doses, day 1-3
or 1-5
etoposide: 500 mg/m2; fractionated doses, day 1-3
or 1-5
bleomycin: 30 u.; days 2, 8, 15 (21-day cycle)
In a 2-3-4 and 6 BEP cycles regime.
The MultiVision PGT test
In the course of the cytogenetic studies we used the MultiVysion
PGT test (VYSIS) for the simultaneous detection of aneuploidy
of chromosomes 13, 18, 21, X and Y within decondensed
spermatozoal heads.
The seminal samples were centrifuged (1700 revolutions/5
minutes). The sediment was then suspended in PBS (buffered
solution of saline with calcium chloride and magnesium chloride;
pH 7) in a temperature of 37°C. After supernatant decantation
cytogenetic specimens were prepared. They were dried on plates
heated to 60°C and then underwent 20 minute fixation in cooled
Carnoy solution (3:1 methyl alcohol and glacial acetic acid) in
vessels used for histological staining. The spermatozoal heads
were decondensed in a 25mM solution of DTT/2xSSC (DDT –
commercially available solution of dithiothreitol, Sigma; SCC
– 0.015M natrium citrate) for 3 minutes in 37°C, rinsed in 2xSCC
for 30 minutes in 37°C and, finally, dehydrated in a series of
increasing concentrations of alcohol solutions (70%, 80%, 95%).
We used the commercially available MultiVysion PGT test,
which includes probes specific for chromosomes 13 (13q14), 18
(D18Z), 21 (21q22.13), X(DXZ1) and Y(DYZ3). Each probe
was directly labeled with fluorochrome – SpectrumRed,
SpectrumAqua, SpectrumGreen, SpectrumBlue and
SpectrumGold, respectively. All the stages of FISH assessment
were performed in exact accordance with the manufacturer’s
instructions. The cytogenetic samples were assessed with the
Nikon Microphot FXA microscope with monostriatic optical
filters – FITC (b-2A; Nikon), TRITC (G-2A; Nikon), Blue
(VYSIS), Aqua (VYSIS), Yellow (VYSIS). The microscopic
scans were registered by a monochromatic, cooled CCD
Photometrics camera (Photometrics Quantix, KAF 1400) and
analyzed with Multi-Scan software for image analysis (Computer
Scanning System).
This particular choice of probes arose from the fact that
only aneuploidies of spermatozoal chromosomes 13, 18, 21, X
and Y may present in live-born children; being observed in
0.31% of neonates [15]. The trisomies and monosomies of all
other chromosomes are lethal during embryogenesis.
S t a t i s t i c a l  m e t h o d s
The results were analyzed with Student’s t-test (CSS-Statistica
5.0). Values are given as mean ± standard deviation; minimum-
maximum.
Results
Altogether we assessed 92800 spermatozoa obtained from
patients before chemotherapy, 48500 spermatozoa
obtained after chemotherapy and 61331 spermatozoa
obtained from the control group. The mean number of
spermatozoa analyzed in a single seminal sample was
approximately 3000. However, 3 patients after chemo-
therapy failed to produce such a number of spermatozoa
per sample due to profound oligozoospermia.
The chosen method of decondensation allowed to
maintain optimal morphology of spermatozoal heads and
preserved the structures of spermatozoal tails. Decon-
densation also provided significant background reduction,
which, in turn, allows for a clearer interpretation of the
results, especially in view of the simultaneous use of five
probes.
In case of both the control group and the patient
group before chemotherapy the efficacy of hybridization
exceeded 90%. On the other hand, in the post-chemo-
therapy group it was significantly lower, not exceeding
60%.
Analysis of the number of obtained hybridization
signals read by the probes allowed to determine the
presence of aberrations in the number of copies of the
investigated chromosomes. Two signals signified disomy.
In such spermatozoa the overall number of chromosomes
was increased (they were hyperhaploidal; i.e. >1n). Lack
of signal was a sign of nullsomy (lack of chromosomal
copy; i.e. < 1n – hypohaploidal spermatozoa). If doubled
signals were discerned on all the probes simultaneously
they signified the presence of a double chromosme set
within the cell, i.e. diploidy (2n).
On applying the FISH technique with chromosomal
centromer probes for chromosomes 13, 18, 21, X and
Yto the spermatozoal samples of both the patients and
the controls the following types of cells were identified:
(i) normal haploidal spermatozoa giving off a single
hybridization signal from all the analyzed chro-
mosomes – a feature characteristic for mono-
somy,
(ii) aneuploidal spermatozoa with no hybridization
signal for one of the analyzed chromosomes –
a feature characteristic for nullsomia,
(iii) diploidal spermatozoa releasing two hybridization
signals for each of the analyzed chromosomes.
The percentages of the different types of sperma-
tozoa acc. to the number of chromosomes are presented
in Table II. No statistically significant differences were
found between the groups.
The percentages of aneuploidal spermatozoa are
compared in Table III. No statistically significant
differences were found between the groups.
Table IV presents the populations of hyperhaploidal
spermatozoa – i.e. those with autosomal disomy. No
statistically significant differences were found between
the groups.
Table V presents the populations of hypohaploidal
cells i.e. without one of the analyzed chromosomes. No
statistically significant differences were found between
the groups.
Table VI presents the populations of spermatozoa
according the number of X and Y chromosomes. The
differences do not reach statistical significance. The mean
percentages of spermatozoa containing both the X and Y
chromosomes were significantly higher (p<0.05) than
the percentages of XX and YY spermatozoa. All the
other differences did not reach statistical significance.
Spermatozoa nullsomic as to the XY chromosomes
constituted 0.14% in the control group, 0.19% in the
group of patients before chemotherapy and 0.13% in the
103
same group after chemotherapy. These values also failed
to reach statistical significance.
Table VII presents the different forms of sperma-
tozoa with diploid (2n) sets of chromosomes comparing
them to the XY chromosomes in the analyzed semen
samples. In the control group diploid karyotype XX
spermatozoa constituted 0.05%, XY – 0.49% and YY –
0.09%. In the patient group these values reached 0.09%,
0,5% and 0.07% before chemotherapy and 0.09%, 0.49%
and 0.07% after chemotherapy. The differences between
the three groups did not reach statistical significance;
diploidal XY spermatozoa were more common (p<0.05)
than the XX and YY spermatozoa in all the three groups.
Spermatozoa with disomy of sex chromosome were
much more common (p<0.05) than spermatozoa with
autosomal disomy (13, 18 and 21). Such differences
were observed in all the three groups, which suggests
104
Table II. Differentiation of the spermatozoal population within the seminal sample acc. to the number of chromosomes
Group Spermatozoa with an anueuploidal no. of chromosomes (%)
(no. of pts. analyzed) Spermatozoa with Spermatozoa with Spermatozoa with Diploidal Aneuploidal
haploidal hypohaploidal hyperhaploidal spermatozoa spermatozoa 
karyotype (%) karyotype karyotype (%) 2n summed
<1n (%) >1n (%) (%)
Controls (5) 98.24 0.40 0.73 0.63 1.76
Pts. before chth (20) 98.0 0.40 0.91 0.69 2.00
Pts. after chth (20) 97.91 0.45 0.97 0.67 2.09
1n – 23 chromosomes / cell >1n – >23 chromosomes / cell
<1n – < 23 chromosomes / cell 2n – 46 chromosomes / cell
Table III. Differentiation of aneuploidal cells in the examined seminal samples
Group Spermatozoa with aneuploidal karyotype 100%
(no. of pts. analyzed) Hypohaploidal spermatozoa <1n (%) Hyperhaploidal spermatozoa >1n (%) Diploidal spermatozoa 2n (%)
Control (5) 22.70 41.50 35.80
Pts. before chth (20) 25.98 42.12 31.90
Pts. after chth (20) 20.40 47.10 32.50
1n – 23 choromosomes / cell >1n – >23 chromosomes / cell
< 1n – <23 chormosomes / cell 2n – 46 chromosomes / cell
Table IV. Hyperhaploidal spermatozoa ratio (mean ± standard deviation)
Group Autosomes (%)
(no. of pts. analyzed) 13 18 21 Total
Control (5) 0.23±0.25 0.20±0.31 0.21±0.07 0.64
Before chth (20) 0.25±0.35 0.24±0.31 0.25±0.24 0.74
After chth (20) 0.31±0.40 0.23±0.35 0.29±0.20 0.83
Table V. Hypohaploidal nullosomic cells (mean ± standard deviation)
Group Chromosomal nullosomies %
(no. of pts. analyzed) 13 18 21 X/Y
Control (5) 0.13±0.09 0.09±0.12 0.07±0.05 0.14±0.14
Before chth (20) 0.08±0.15 0.08±0.08 0.08±0.06 0.19±0.19
After chth (20) 0.09±0.24 0.04±0.17 0.04±0.07 0.13±0.13
Table VI. Results of analysis of number of copies of sex chromosomes X/Y (mean ± standard deviation)
Group Normal spermatozoa Disomies Nullsomies
(no. of pts. analyzed) X (%) Y (%) XX (%) XY (%) YY (%) X/Y (%)
Control (5) 48.24±3.40 51.76±3.40 0.075±0.10 0.50±0.28 0.14±0.15 0.14±0.14
Before chth (20) 45.8±3.40 54.2±3.40 0.19±0.10 0.49±0.40 0.12x0.12 0.19±0.19
After chth (20) 47.6±2.9 52.4±2.9 0.15x0.10 0.50x0.50 0.15±0.15 0.13±0.13
a significantly higher incidence of disomy of the sex
chromosomes.
Discussion
Our knowledge concerning the cytogenetic disorders of
spermatozoa after chemotherapy remains incomplete.
Some congenital diseases (such as Down syndrome or
Patau syndrome) arise from evident genetic disorders of
reproductive cells, although we are not aware of the
reasons for their appearance nor of their relationship
with parental exposure to noxious stimuli. Only a few
papers concerning this subject have been published to
date, and they contain contradictory data. In all these
reports very few cases are reported (4-5 pts) [15-19]. Data
concerning the influence of chemotherapy on the
frequency of spermatozoal chromosome aberrations
(evaluated with FISH and acc. to Yanagimachi modified
by Brandiff) is also contradictory. Genesca and other
authors have reported a significant increase of numerical
and structural aberrations of spermatozoal chromosomes
observed during the first 2-7 years after the completion of
chemotherapy [16, 18]. On the other hand the study of
Martin conducted on a group of patients between 2 and
13 years after the completion of chemotherapy [19] did
not confirm the former findings.
The FISH technique (fluorescent in situ hybridiza-
tion) has been used for over a decade to evaluate the
frequency of chromosomal aneuploidy in the male
reproductive cells of sperm donors, patients with gonadal
tumours and carriers of balanced structural aberrations.
Similar analyzes are also performed in men, whose
offspring present with aneuploidy of chromosomes 21, X
and Y in order to assess the risk of genetic defects in
other children. Attempts have been made to analyze the
connection between the age of the father and the risk of
producing a child with a defective fenotype arising from
chromosomal aneuploidy. The FISH technique has
also been used to assess chromosomal structural
aberrations in spermatozoa [20, 21]. There also exist
pioneer studies in which hybridization was performed
with the painting probe specific for one chromosome only
[21]. However, such an approach does not allow to discern
between disomic and diploidal spermatozoa and between
nullsomic and non-informative (non-hybridized) sperma-
tozoa. Attempts have been made to discern diploidal and
disomic spermatozoa according to the size of the head.
However, the correlation between the size of the head
and the diploidal karyotype does not appear convincing,
all the more so because in the course of decondensation
the spermatozoal head increases [20]. The use of FISH
with two molecular probes allows for a more exact
evaluation of aneuploidy of spermatozoal chromosomes.
The probability of simultaneous disomy of both the
analyzed chromosomes (two hybridization signals) is so
low, that a reading of double disomy may be interpreted
as diploidy. This allowed to discern between diploidy and
disomy, and also enabled us to evaluate the efficacy of the
method. Concomittant use of three probes – two homo-
logous for the X and Y chromosomes and one autosomal
chromosome has allowed to evaluate the ploidy of the
chromosomes [20].
The application of FISH with the simultaneous use
of several molecular probes allows for a precise evaluation
of the frequency of chromosomal ploidy in human
spermatozoa [22]. When conducted in healthy, fertile
men such studies enable us to assess the frequency of
aneuploidy in each and every one chromosome of the
human genome [22]. In his study Bernardini has shown
that the frequency of aneuploidy of the studied sperma-
tozoal chromosomes varies among the subjects, remaining
between 0.01% and 0.4% [22]. These variations are
probably caused by differences brought on by the method
or by the criteria applied during specimen analysis in the
different laboratories. They may also arise from individual
variations between sperm donors.
In the studies concerning the frequency of chromo-
somal aberrations in the spermatozoa of patients with
testicular cancer after orchidectomy alone this parameter
showed no increase, as compared to healthy men in
comparable age groups [15, 23].
Recent studies have been aimed at the influence of
chemotherapy on the frequency of aneuploidy of chosen
chromosomes [16, 18, 19]. Reports on the impact of
chemotherapy on the frequency of aneuploidy of sperma-
tozoal chromosomes present differing results.The FISH
technique with the use of probes specific for chromoso-
mes 1, 12, X and Y has been used to analyze spermatozoa
obtained from patients after chemotherapy with the
MACOP-B regime (methotrexate, leucovorin, doxorubi-
cin, cyklophosphamide, vincristine, prednisone and
bleomycin) [24]. In this material the frequency of sperma-
tozoa with disomy did not differ from their frequency in
the control group, reaching 0.1% for chromosome 1,
0.11% for chromosome 12, 0.05% for chromosome XX,
0.05% for chromosome YY and 0.18% for chromoso-
me XY.
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Tabela VII. Differentiation of diploidal spermatozoa in relation to sex chromosome status in the examined seminal samples 
(mean ± standard deviation)
Group Diploidal XX Diploidal XY Diploidal YY 
(no. of pts. analyzed) chromosome spermatozoa (%) chromosome spermatozoa (%) chromosome spermatozoa (%)
Control (5) 0.05±0.09 0.49±0.27 0.09±0.15
Before chth (20) 0.09±0.11 0.50±0.34 0.07±0.08
After chth (20) 0.09±0.06 0.49±0.26 0.07±0.12
Similar studies were conducted in testicular cancer
patients before and after chemotherapy with platin
preparations. The results show a similar frequency of
disomy of all the analyzed chromosomes – i.e. 0.11% and
0.06% respectively for chromosome 1; 0.18% and 0.15%
for chromosome 12; 0.1% and 0.9% for chromosome
XX; 0.13% and 0.1% for chromosome YY and 0.25%
and 0.2% for chromosome XY [23]. However, there exist
reports of a significant increase of the frequency of XY
disomy in testicular cancer patients before (0.33%) and
after (0.34%) chemotherapy acc. to the BEP regime, as
compared to its frequency before treatmen – i.e. 0.14%
[25]. A significant, though transient, increase in the
hyperhaploidy of chromosomes 1, 12, X and Y has also
been observed in men with Hodgkin’s disease who had
undergone NOVP treatment (novantrone, vincristine,
vinblastine and prednisone). The percentages of aneu-
ploidal spermatozoa decreased to pre-treatment values
100 days after chemotherapy application.
The present study was the first in which simultaneous
hybridization with five probes (specific for chromosomes
13, 18, 21 X and Y) was performed in spermatozoal
specimens. These particular chromosomes were chosen
because only their numerical aberrations are discerned
postnataly. The basic profit from this diagnostic approach
is the possibility of evaluating the frequency of ploidy of
five pairs of homologous chromosomes during a single
analysis and in a relatively short period of time. Con-
ducting such a complex analysis in one sperm sample is all
the more important in subjects in whom it is difficult to
obtain an adequate amount of semen and in subjects with
profound oligozoospermia.Our results have not revealed
any statistically significant differences between testicular
cancer patients before and after chemotherapy and
between these two groups and healthy controls regarding
the frequency of aneuploidy of chromosomes 13, 18, 21, X
and Y.
The statistically insignificant differences in the ratio
of aneuploidal spermatozoa which we have observed may
be caused either by individual variations or may depend
on the age of the patients. The mean percentage of XY
disomy spermatozoa were significantly (p<0.05) higher
than the percentages of XX and YY disomy spermatozoa.
Also disomy of sex chromosomes was more common than
disomy of autosomal chromosomes (13, 18 and 21).
Errors occurring during the first meiotic division are
usually responsible for the lack of division of mother-
derived chromosomes, while errors occurring during the
second meiotic division are responsible for the lack of
division of father-derived chromosomes. Additionally all
errors of the first meiotic division (both mother- and
father-derived) may cause a decrease in the frequency
of recombinations, and thus predispose to the lack of
chromosome division due to the loss of heterozygocity.
The lack of recombination within the PARX and PARY
has been described in literature. It a majority of cases it
presents as 47,XXY. A similar decreased frequency of
recombinations may observed in the case of pairs of
acrocentric chromosomes [27]. The highly frequent
appearance of XY spermatozoa (lack of division of
chromosomes during the first meiotic division)as
compared to XX and YY spermatozoa (lack of division of
chromosomes during the second meiotic division) nay
suggest that errors are more common during the first
meiotic division. However the results are not easy to
interpret, especially because similar observations have
also been made in the control group. This may suggest
that the above-mentioned phenomenon may not be an
effect of treatment but, rather, arises from the variations
ion the patient’s age (over 25 years).
It is also interesting to note that we have observed
a relatively low percentage of X and Y nullsomic
spermataozoa (0.028% – 0.05%) although in 80% of cases
of X monosomy the lost X chromosome is father-derived.
It may suggest that monosomy of the mother-derived X
chromosome may be caused by postzygotic mitotic errors,
which cause the loss of the father-derived X chromosome.
It may be connected with some form of father-dependant
genomic imprinting which may affect some yet uniden-
tified sequences localized within the X chromosome,
which in turn causes a tendency to lose the father-derived
X chromosome.
Our results show testicular cancer patients have
a low risk of producing a child with chromosome 13, 18,
21, X or Y aneuploidy 30 months after the administration
of platin oncolytics. One cannot rule out the possibility
that platin oncolytics do cause transient chromosomal
aneuploidy in the analyzed group of patients. However, all
patients were studied 30 months after the completion of
oncolytic treatment and therefore such a transient effect
may have been lost from observation. On presenting these
patients with a medical opinion one cannot forget about
all other factors responsible for generating aneuploidal
karyotypes. According to present day knowledge these
patients should be referred to Genetic Clinics and,
possibly, advised to perform pre-natal diagnostics.
Evaluation of the frequency of spermatozoal chro-
mosomal aberrations is, at present, of crucial importance
in sperm donors-carriers of balanced chromosomal
aberrations (translocations, insertions and marker
chromosomes) and in cancer patients in whom chemo-
therapy and/or radiotherapy are scheduled. Multicoloured
FISH technique may be helpful in defining the risk of
aneuploidy of chromosomes 13, 18, 21, X and Y in these
two groups, especially in subjects with profound oligo-
zoospermia. When accompanied by other diagnostic tools
the FISH technique may allow to evaluate the important
prognostic factors affecting the choice of the optimal
treatment methods.
The ratio of spermatozoa containing the X chro-
mosome as compared to spermatozoa containing the Y
chromosome reached 48.24% and 51.76% in the control
group; 45.80% and 54.20% in patients before chemo-
therapy and 47.60% and 52.40% in patients after
chemotherapy. In a majority of cases we observed a slight
increase in the percentage of Y-chromosome containing
spermatozoa. However the differences in the ratios of X
chromosome spermatozoa and Y chromosome sperma-
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tozoa did not achieve statistical significance in any of the
three groups. Thus we have found no statistically
significant variation of the 50%: 50% X:Y ratio. Our
results remain in concordance with the results published
by other authors [17, 24].
Conclusions
Aneuploidy of chromosomes 13, 18, 21, X and Y is as
common among healthy men as in a group of testicular
cancer patients.
The use of platin-derived oncolytics does not affect
the frequency of chromosome 13, 18, 21, X and Y aneu-
pliody in testicular cancer patients 30 months after the
completion of therapy.
Tomasz Demkow MD, PhD
Department of Urological Oncology
The Maria Sklodowska-Curie Memorial Cancer Center
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